Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Grandjean, Capucine L ^a,b   Montalvao, Fabricio ^a,b   Celli, Susanna ^a,b   Michonneau, David ^a,b   Breart, Beatrice ^a,b   Garcia, Zacarias ^a,b   Perro, Mario ^c   Freytag, Olivier ^c   Gerdes, Christian A ^c   Bousso, Philippe ^a,b  

^a INSTITUT PASTEUR   (France)

^b INSTITUT PASTEUR   (France)

^c Roche Pharmaceutical Research Early Development   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; MONOCLONAL ANTIBODY; OBINUTUZUMAB; RITUXIMAB;

ANIMAL; B LYMPHOCYTE; DIAGNOSTIC IMAGING; DRUG EFFECT; GENETICS; IMMUNOLOGY; INTRAVITAL MICROSCOPY; KNOCKOUT MOUSE; KUPFFER CELL; LIVER; LIVER TRANSPLANTATION; LYMPHOCYTE DEPLETION; MOUSE; PATHOLOGY; PHAGOCYTOSIS; PROCEDURES; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD20; B-LYMPHOCYTES; INTRAVITAL MICROSCOPY; KUPFFER CELLS; LIVER; LIVER TRANSPLANTATION; LYMPHOCYTE DEPLETION; MICE; MICE, KNOCKOUT; PHAGOCYTOSIS; PROTEIN ENGINEERING; RITUXIMAB;

EID: 84989874901     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep34382     Document Type: Article

References (21)

1. Lim, S. H., et al. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 95, 135-143 (2010
2. Chan, A. C., & Carter, P. J. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10, 301-316 (2010
3. Maloney, D. G. Anti-CD20 antibody therapy for B-cell lymphomas. The New England journal of medicine 366, 2008-2016 (2012
4. Glennie, M. J. French, R. R. Cragg, M. S., & Taylor, R. P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44, 3823-3837 (2007
5. Montalvao, F., et al. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J Clin Invest 123, 5098-5103 (2013
6. Gul, N., et al. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest 124, 812-823 (2014
7. Gong, Q., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. Journal of immunology 174, 817-826 (2005
8. Umana, P. Jean-Mairet, J. Moudry, R. Amstutz, H., & Bailey, J. E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nature biotechnology 17, 176-180 (1999
9. Ferrara, C. Stuart, F. Sondermann, P. Brunker, P., & Umana, P. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 281, 5032-5036 (2006
10. Jefferis, R. Glycosylation as a strategy to improve antibody-based therapeutics. Nature reviews. Drug discovery 8, 226-234 (2009
11. Herter, S., et al. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol 192, 2252-2260 (2014
12. Kamada, N., & Carne, R. Y. Orthotopic liver transplantation in the rat. Technique using cuff for portal vein anastomosis and biliary drainage. Transplantation 28, 47-50 (1979
13. Germain, R. N. Robey, E. A., & Cahalan, M. D. A decade of imaging cellular motility and interaction dynamics in the immune system. Science 336, 1676-1681 (2012
14. Bousso, P., & Moreau, H. D. Functional immunoimaging: the revolution continues. Nature reviews. Immunology 12, 858-864 (2012
15. Ferrara, C., et al Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-Acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnology and bioengineering 93, 851-861 (2006
16. Uchida, J., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. The Journal of experimental medicine 199, 1659-1669 (2004
17. Beers, S. A., et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115, 5191-5201 (2010
18. Mossner, E., et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115, 4393-4402 (2010
19. Herter, S., et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Molecular cancer therapeutics 12, 2031-2042 (2013
20. Goede, V., et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370, 1101-1110 (2014
21. Tipton, T. R., et al. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. Blood 125, 1901-1909 (2015